Embecta News
News
0
Ticker
EMBC
ISIN
US29082K1051
Embecta Eulerpool News
Embecta Stock News
Embecta is being monitored by journalists and investors worldwide. We gather the latest Embecta news here.
- March 19·SeekingAlpha
- March 19·Benzinga
- March 10·Benzinga
- February 12·Yahoo
- February 11·Yahoo
- February 11·Yahoo
- February 6·Yahoo
- February 6·SeekingAlpha
- February 5·SeekingAlpha
- February 5·ChartMill
- February 5·Yahoo
- February 5·Benzinga
- January 22·Yahoo
- November 29·SeekingAlpha
- November 26·SeekingAlpha
- November 25·Yahoo
- November 25·SeekingAlpha
- November 25·SeekingAlpha
- November 25·Benzinga
- November 20·Yahoo
Embecta Stock Press Releases
Embecta regularly publishes news on the company's website that are relevant for investors.
Embecta News 2026
This page contains all current news, analysis and press releases for Embecta stock (EMBC, ISIN: US29082K1051). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Embecta.
Embecta Stock
Embecta Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management.